Data completeness
2/8 — Basic
Ruxolitinib (ruxolitinib) by Incyte is janus kinase inhibitors [moa].
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ruxolitinib is an oral small-molecule Janus Kinase (JAK) inhibitor developed by Incyte for oral administration as a tablet. The drug modulates JAK-mediated inflammatory and proliferative pathways, with applications across multiple therapeutic areas. Specific indications are pending commercial launch confirmation.
Pre-Launch
Pre-launch stage signals active team building across commercial, medical, and regulatory functions as Incyte prepares market entry.
Mechanism of Action
Janus Kinase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Belumosudil Versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD
Started Oct 2026
170 enrolled
Hematopoietic Stem Cell Transplantation (HSCT)cGVHDHepatic cGVHD+2 more
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Started Sep 2026
324 enrolled
MyelofibrosisAnemia
Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum
Started Sep 2026
12 enrolled
Pyoderma Gangrenosum
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Started Aug 2026
268 enrolled
MyelofibrosisMyelofibrosis (MF)
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
Started Aug 2026
15 enrolled
Myelofibrosis
Worked on Ruxolitinib at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.